🔗 Share this article

While the United States continues making unprecedented revisions to its vaccination recommendations, a particular individual has surfaced unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who rose to prominence by questioning Covid shots throughout the pandemic and has focused upon alleged deaths after COVID-19 vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Proposed Changes to Childhood Vaccine Schedule

Public health authorities were set to announce radical revisions to the childhood vaccination calendar recently, synchronizing the US with Denmark’s national calendar, it is understood – a substantial departure that would place the US at odds with a large portion of the world with no evidence for public health gain. The planned update has been postponed until the next year.

In place of the director of the vaccine center, Tracy Beth Høeg is set to present at the event. She was recently named interim head of the FDA’s CDER, the fifth individual to lead the division this calendar year.

Consolidating Power at the FDA

This interim role may indicate a strengthened alliance between the drug and biologics centers as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it points to a renewed priority upon dismantling long-standing vaccines at the FDA.

Høeg has often pushed for halting specific pediatric shot schedules in the US to become more similar to Denmark's approach, a nation with comprehensive healthcare and a population roughly the population of Wisconsin’s.

So far comments, she has persisted in emphasizing on immunizations – traditionally the responsibility of Prasad, chief of the FDA’s vaccine center – as opposed to medication approval.

Doubts Over Background

Dr. Høeg has little discernible background in drug development, approval processes or administrative roles, which has been standard for former leaders of the biologics center. She has worked at the FDA as a key advisor to the FDA chief and CBER since spring.

“It seems she lacks to have the requisite experience” for running the pharmaceutical oversight division, stated Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in leading a sizeable institution. She has no expertise in industry regulation.”

Former heads of CBER would “understand regulatory frameworks and the science of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Frankly, she lacks the sort of resume that previous people who ran CBER have had.”

This division has an vast range of responsibilities at the agency, the former commissioner stated.

“The public just pays attention on the new drug program, but the generic drug division clears thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, over-the-counter program and other areas, and each of these need to be managed,” Dr. Woodcock said. “The responsibility you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a substantial administrative component to the job, which supervises in excess of 5,000 employees. “It is a massive administrative position, if you execute it properly,” the former official said.

Official Statement and Contentious Programs

In response to questions about Dr. Høeg's fitness for the role and whether this appointment represents greater collaboration among agency officials on immunizations, a representative said that the “concerns rely on flawed assumptions”.

“Her resume aligns with the responsibilities of her position,” the spokesperson explained, noting the period Høeg spent guiding the FDA commissioner on “medication safety and approval science, including computerized risk analysis and vaccine surveillance”.

As acting director, Høeg takes over the commissioner’s controversial expedited review system, a contentious expedited drug-approval program that allegedly troubled her preceding directors. “How are these therapies being selected for this fast-track system? Who makes the calls?” Howard said. “There’s a lot of secrecy happening at the regulatory body right now.”

Overall, he said, “the agency seems to be moving towards more relaxed regulations of all drugs, except for vaccines.”

Documented Track Record on Immunizations

Regarding immunizations, Dr. Høeg has a more established, if concerning, past, Howard observe. She published a analysis using unconfirmed public submissions to determine the rate of myocarditis after Covid immunization. She consulted for the Florida surgeon general Joseph Ladapo, who was said to have altered data to suggest COVID-19 vaccines are more dangerous than they are.

Part of her “policy goals” for the current administration featured changing guidelines for recently developed shots and discontinuing “non-essential” vaccines, she remarked after the election on a online show. At the FDA, Høeg has allegedly proposed barring teenage boys from getting COVID-19 vaccinations.

“She is an complete dogmatist who commences with her conclusions and works backwards to fit the data in a highly disingenuous, fraudulent manner,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg became part of fellow dissenters, {like|